Covering the current state of equity markets, COVID-19 outlook and portfolio positioning (10 mins).
The RooLife Group provides fully integrated digital marketing and customer acquisition services, focusing on driving online sales of products and services for its clients. Powered by the company’s proprietary hyper-personalisation and profiling Artificial Intelligence System, RooLife provides personalised, real-time, targeted marketing.
With a key focus on driving sales in Australia and China the Company’s online eCommerce marketplaces assist businesses to sell directly to Chinese consumers and accept payment via the WeChat and Alipay mobile payments platforms. RooLife’s key positioning is about knowing and remaining connected with Chinese consumers, allowing brands to effectively sell products to Chinese Consumers based on their profiles and purchasing behaviours.
Nutritional Growth Solutions was established at Schneider Children’s Medical Center of Israel by a professional team that focuses research on the interaction between nutrition and growth. Pediatricians at Schneider have over 20,000 patient visits every year from children living around the globe with issues relating to growth.
This has spurred these world-renowned scientists, doctors, and researchers to focus on nutritional growth retardation in children and adolescents. Schneider’s experts use this wealth of practical and clinical knowledge to develop evidence-based clinically tested nutritional solutions for children.
Nyrada is an Australian publicly-listed (ASX: NYR) preclinical stage, drug development company. The Company specialises in the development of novel small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases.
The Company’s vision is to become a high growth pharmaceutical company specialising in drug discovery and early stage drug development. The Company focuses on areas of substantial unmet clinical need and has identified drug candidates with significant therapeutic and commercial potential, where few if any, effective or well-tolerated therapies exist.
More to follow ...
Peter Gillespie - Mobile: 0413 807 797 Email: email@example.com
Sasho Sokolovski - Mobile: 0409 965 427 Email: firstname.lastname@example.org
If you would like to have further information on any of FNN's events, please contact +61 2 8294 4302